SA-QS3 - komunikat spółki KRKA, TOVARNA ZDRAVIL D.D. (krka) - komunikat ESPI

Komunikat spółki

COMMON REPORT

	POLISH FINANCIAL SUPERVISION AUTHORITY
				UNI - EN REPORT No		49	/	2024
	Date of issue:		2024-11-14
	Short name of the issuer
	KRKA
	Subject
	Unaudited interim report of the Krka Group and Krka, d. d., for the period January to September 2024
	Official market - legal basis
	art. 17. 1 MAR.
	Unofficial market - legal basis
	Contents of the report:
	Based on Article 26 of the Rules of the Ljubljana Stock Exchange d.d. company Krka, d. d., Novo mesto publishes The unaudited interim report of the Krka Group and Krka, d. d., Novo mesto for the nine months ended 30 September 2024. The report will be published on the Company's website (www.krka.biz) from 14 November 2024 onwards, for a period of at least 5 years.
	Annexes
	File				Description
	Unaudited Interim report of the Krka Group and Krka, d. d., Novo mesto for the nine months ended 30 September 2024.pdf				Unaudited Interim report of the Krka Group and Krka Company for January-September 2024
	Press Release.pdf				Press Release

KRKA, TOVARNA ZDRAVIL D.D.

(fullname of the issuer)

KRKA

Farmaceutyczny (far)

(short name of the issuer)

(sector according to clasification of the WSE in Warsow)

8501

Nove Mesto

(post code)

(city)

Smarjeska

6

(street)

(number)

+386 7 331 21 11

+386 7 332 15 37

(phone number)

(fax)

(e-mail)

(web site)

nie dotyczy

(NIP)

(REGON)

	SIGNATURE OF PERSONS REPRESENTING THE COMPANY
	Date	Name	Position / Function	Signature
	2024-11-14	Jože Colarič	President of the Management Board and CEO

Nazwa jednostki:	KRKA, TOVARNA ZDRAVIL D.D.
Nazwa skrócona jednoskti:	KRKA
Adres:	Smarjeska 6, 8501 Nove Mesto
Telefon:	+386 7 331 21 11
Fax:	+386 7 332 15 37
NIP:	nie dotyczy